Also known as: LY3437943|GGG Agonist
Retatrutide is a novel peptide classified as a triple GLP-1/GIP/glucagon agonist, primarily categorized under fat loss and metabolic peptides. This compound is designed to target multiple pathways involved in metabolism and energy regulation, making it a significant focus in obesity and metabolic disorder research. By mimicking the action of natural hormones, Retatrutide aims to influence body weight and metabolic health.
Retatrutide operates by activating three key receptors: GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and glucagon. This multi-receptor activation enhances insulin secretion, reduces appetite, and increases energy expenditure.
The combined effects of these actions contribute to improved glucose metabolism and fat loss, making Retatrutide a promising candidate for addressing obesity and related metabolic conditions. Its unique mechanism allows for a synergistic approach to metabolic regulation, potentially leading to more effective outcomes than single-target therapies.
Retatrutide represents a significant advancement in the field of metabolic peptides, targeting multiple pathways to aid in weight management and metabolic health. Its unique mechanism of action positions it as a valuable tool in research aimed at combating obesity and improving overall metabolic function.
Last updated: Feb 25, 2026